Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Table 2 Drug dosing for the endTB-Q experimental arm

Drug	Weight band (kg)
Drug	24–30	> 30
Bedaquiline	200 mg daily for 2 weeks followed by 100 mg 3 × /week	400 mg daily × 2 weeks followed by 200 mg 3 × /week
Clofazimine	100 mg daily	100 mg daily
Delamanid	50 mg twice daily	100 mg twice daily
Linezolid^a	300 mg daily up to week 16 (followed by 300 mg daily or 600 mg 3 × /week)	600 mg daily up to week 16 (followed by 300 mg daily or 600 mg 3 × /week)

^aLinezolid dosing is routinely modified at week 16, or sooner if necessary, to reduce toxicity related to linezolid. The modification is either decreased (300 mg daily) or intermittent (600 mg 3 × /week) dosing as defined by a balanced secondary randomization

ISSN: 1745-6215